|
1
|
Cook AD, Single R and McCahill LE:
Surgical resection of primary tumors in patients who present with
stage IV colorectal cancer: An analysis of surveillance,
epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol.
12:637–645. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nordlinger B, Van Cutsem E, Rougier P,
Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A,
Georgoulias V, et al: Does chemotherapy prior to liver resection
increase the potential for cure in patients with metastatic
colorectal cancer? A report from the European Colorectal Metastases
Treatment Group. Eur J Cancer. 43:2037–2045. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Van den Eynde M and Hendlisz A: Treatment
of colorectal liver metastases: A review. Rev Recent Clin Trials.
4:56–62. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Poston GJ, Figueras J, Giuliante F, Nuzzo
G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti
MA, et al: Urgent need for a new staging system in advanced
colorectal cancer. J Clin Oncol. 26:4828–4833. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Abdalla EK, Vauthey JN, Ellis LM, Ellis V,
Pollock R, Broglio KR, Hess K and Curley SA: Recurrence and
outcomes following hepatic resection, radiofrequency ablation, and
combined resection/ablation for colorectal liver metastases. Ann
Surg. 239:818–825; discussion 825-827. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Oba M, Hasegawa K, Shindoh J, Yamashita S,
Sakamoto Y, Makuuchi M and Kokudo N: Survival benefit of repeat
resection of successive recurrences after the initial hepatic
resection for colorectal liver metastases. Surgery. 159:632–640.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mitry E, Fields AL, Bleiberg H, Labianca
R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, et
al: Adjuvant chemotherapy after potentially curative resection of
metastases from colorectal cancer: A pooled analysis of two
randomized trials. J Clin Oncol. 26:4906–4911. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bokemeyer C, Van Cutsem E, Rougier P,
Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH:
Addition of cetuximab to chemotherapy as first-line treatment for
KRAS wild-type metastatic colorectal cancer: Pooled analysis of the
CRYSTAL and OPUS randomized clinical trials. Eur J Cancer.
48:1466–1475. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Folprecht G, Gruenberger T, Bechstein WO,
Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher
J, Weitz J, et al: Tumour response and secondary resectability of
colorectal liver metastases following neoadjuvant chemotherapy with
cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol.
11:38–47. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shin SJ, Ahn JB, Choi JS, Choi GH, Lee KY,
Baik SH, Min BS, Hur H, Roh JK and Kim NK: Implications of clinical
risk score to predict outcomes of liver-confined metastasis of
colorectal cancer. Surg Oncol. 21:e125–e130. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lambert LA, Colacchio TA and Barth RJ Jr:
Interval hepatic resection of colorectal metastases improves
patient selection. Arch Surg. 135:473–479; discussion 479-480.
2000.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nishioka Y, Moriyama J, Matoba S,
Kuroyanagi H, Hashimoto M and Shindoh J: Prognostic impact of
adjuvant chemotherapy after hepatic resection for synchronous and
early metachronous colorectal liver metastases. Dig Surg.
35:187–195. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Japanese Society for Cancer of the Colon
and Rectum: Japanese Classification of Colorectal Carcinoma. 9th
edition. Kanehara & Co. Ltd., Tokyo, p16, 2018.
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Takatsuki M, Tokunaga S, Uchida S, Sakoda
M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, et al:
Evaluation of resectability after neoadjuvant chemotherapy for
primary non-resectable colorectal liver metastases: A multicenter
study. Eur J Surg Oncol. 42:184–189. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative FOLFOX4 chemotherapy and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): Long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 14:1208–1215.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hasegawa K, Saiura A, Takayama T, Miyagawa
S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H,
et al: Adjuvant oral uracil-tegafur with leucovorin for colorectal
cancer liver metastases: A randomized controlled trial. PLoS One.
11(e0162400)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
de Haas RJ, Adam R, Wicherts DA, Azoulay
D, Bismuth H, Vibert E, Salloum C, Perdigao F, Benkabbou A and
Castaing D: Comparison of simultaneous or delayed liver surgery for
limited synchronous colorectal metastases. Br J Surg. 97:1279–1289.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Ali SM, Pawlik TM, Rodriguez-Bigas MA,
Monson JRT, Chang GJ and Larson DW: Timing of surgical resection
for curative colorectal cancer with liver metastasis. Ann Surg
Oncol. 25:32–37. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yoshita H, Hosokawa A, Ueda A, Ando T,
Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, et
al: Predictive value of optimal morphologic response to first-line
chemotherapy in patients with colorectal liver metastases.
Digestion. 89:43–48. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chun YS, Vauthey JN, Boonsirikamchai P,
Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H,
Charnsangavej C and Loyer EM: Association of computed tomography
morphologic criteria with pathologic response and survival in
patients treated with bevacizumab for colorectal liver metastases.
JAMA. 302:2338–2344. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shindoh J, Loyer EM, Kopetz S,
Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA,
Charnsangavej C, Aloia TA and Vauthey JN: Optimal morphologic
response to preoperative chemotherapy: An alternate outcome end
point before resection of hepatic colorectal metastases. J Clin
Oncol. 30:4566–4572. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Haller DG: Safety of oxaliplatin in the
treatment of colorectal cancer. Oncology (Williston Park).
14:15–20. 2000.
|
|
25
|
Nakano H, Oussoultzoglou E, Rosso E,
Casnedi S, Chenard-Neu MP, Dufour P, Bachellier P and Jaeck D:
Sinusoidal injury increases morbidity after major hepatectomy in
patients with colorectal liver metastases receiving preoperative
chemotherapy. Ann Surg. 247:118–124. 2008.PubMed/NCBI View Article : Google Scholar
|
